Diabetes and Chronic Kidney Disease Management: A Practical Primary Care Approach

The American Diabetes Association (ADA) Standards of Care in Diabetes – 2026 mark a decisive shift in the management of patients with diabetes and chronic kidney disease (CKD). For primary care physicians (PCPs), who are often the first to detect and manage early kidney dysfunction, the updated guidance calls for:

• Earlier and more frequent CKD screening.
• Greater emphasis on cardiovascular and renal protection, not just glycemic control.
• Increased focus on multidisciplinary, team-based care.

CKD affects an estimated 20% to 40% of patients with diabetes and significantly increases cardiovascular (CV) risk. This dual burden reinforces the central role of primary care in identifying disease early, initiating therapy, and coordinating care across specialties.

“Earlier recognition and treatment before advanced disease develops can meaningfully improve patient outcomes,” stresses Elizabeth Pabon-Vazquez, MD, a nephrologist with Cleveland Clinic Weston Hospital.

Earlier detection, more actionable screening

The latest ADA standards recommend routine screening with urinary albumin-to-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR) in all patients with type 2 diabetes at diagnosis and in those with type 1 diabetes after five years. While annual assessment remains the baseline, the guidance also encourages more individualized and frequent monitoring once CKD is identified – one to four times annually depending on disease stage.

Albuminuria serves as a key early marker of kidney damage and a signal to intensify management. In practice, this means PCPs should not only identify abnormalities but also respond more decisively when uACR rises above 30 mg/g or when eGFR begins to decline.

Dr. Pabon-Vazquez supports a more proactive stance on referral. “I believe that patients who have a GFR less than 60 and have albumin in the urine of more than 30 mg/g should be referred to a nephrologist,” she notes, highlighting the opportunity for earlier intervention during stage 3 CKD.

From glucose control to organ protection

A major evolution in the 2026 standards is the move beyond a glucose-centric model toward a broader focus on organ protection. The Cardiovascular-Kidney-Metabolic (CKM) framework positions diabetes as a condition that simultaneously affects the heart, kidneys, and metabolic systems.

For PCPs, this translates into a more integrated treatment strategy. Glycemic control remains important, but it’s not the sole priority. Clinicians are encouraged to select therapies that reduce risk across multiple organ systems.

This shift is reflected in the prioritization of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. These agents are recommended for their demonstrated benefits in slowing CKD progression and reducing cardiovascular events – independent of A1C.

“When the GFR is between 60 and 30, we have a lot of room to start medications that protect kidney function,” observes Dr. Pabon-Vazquez. “Increased familiarity with these therapies will improve clinician confidence in using them earlier in the disease course.”

A proactive, layered approach

Treatment of CKD in diabetes still begins with foundational therapies, including tight blood pressure control (<130/80 mmHg) and the use of ACE inhibitors or ARBs in patients with hypertension and albuminuria. However, the updated standards encourage earlier intensification when risk persists.

Medication management is best understood as a layered approach. Renin-angiotensin system (RAS) blockade remains the baseline, but additional agents should be introduced when albuminuria is not adequately controlled. The goal is clear: reduce urinary albumin excretion to less than 30 mg/g.

• SGLT2 inhibitors are now central to this strategy, recommended for patients with CKD to reduce both renal and cardiovascular outcomes regardless of glycemic status.
• GLP-1 receptor agonists further support cardiovascular risk reduction and contribute to kidney protection.
• Nonsteroidal mineralocorticoid receptor antagonists (ns-MRA), such as finerenone, provide another option for patients with persistent risk.

Importantly, PCPs should anticipate and monitor expected changes in kidney function after initiating therapy. A modest decline in eGFR may occur, but a reduction greater than 30% should prompt reassessment, cautions Dr. Pabon-Vazquez.

Timely referral and shared management

The updated standards reinforce clear thresholds for nephrology referral, particularly when eGFR falls below 30 mL/min or when significant albuminuria persists. However, there is growing consensus around earlier referral for patients with stage 3 CKD to allow for more comprehensive management and patient education.

At the same time, the increasing complexity of treatment decisions – particularly with newer agents – demands closer collaboration across specialties. PCPs are central to this effort, serving as coordinators of care while initiating and monitoring therapy.

Dr. Pabon-Vazquez highlights the importance of shared decision-making across specialties to optimize both safety and efficacy. “In one recent case, I consulted with a patient’s cardiologist before switching from spironolactone to finerenone to ensure alignment in managing both the patient’s CKD and heart failure,” she explains.

Collaboration with endocrinology is expected to grow as well, particularly around GLP-1 receptor agonist selection. “It’s further evidence we cannot operate in specialty silos,” she says.

The standards also note the need for interdisciplinary coordination in special populations, such as pregnant patients, where medication selection and monitoring require additional considerations.

Foundational lifestyle intervention

Despite advances in pharmacologic treatment, lifestyle modification remains a cornerstone of care. The ADA standards continue to emphasize physical activity, nutrition, weight management, smoking cessation, and blood pressure control as essential components of CKD and diabetes management.

“PCPs play a critical role in initiating and reinforcing these changes, but we all need to be promoting lifestyle modifications,” says Dr. Pabon-Vazquez. “More than medication, they may have the bigger impact on overall disease progression.”

Key takeaways for busy clinicians

The 2026 ADA Standards of Care reflect a transformative shift in the management of diabetes and CKD – one anchored to a CKM framework that reinforces the need for a holistic, patient-centered approach.

To align clinical practice with these evolving standards, PCPs should:

• Screen early and regularly with uACR and eGFR.
• Treat beyond A1C – prioritize kidney and cardiovascular protection.
• Use SGLT2 inhibitors and GLP-1 receptor agonists early in appropriate patients.
• Escalate therapy to reduce albuminuria (<30 mg/g).
• Refer sooner, not later – especially with declining kidney function.
• Embrace team-based care to optimize outcomes.

By focusing on early detection, layered therapy, and multisystem risk reduction, PCPs are well positioned to slow disease progression and improve long-term outcomes for their patients.